A

Allergy, Asthma and Clinical Research Center | Oklahoma City, OK

Research site

(Unclaimed)

Location

4200 W Memorial Road, Suite 206, Oklahoma City, Oklahoma, United States of America

Site insights

Top conditions

Top treatments

Dupilumab

azelastine hydrochloride

Omalizumab

azelastineHcl

Amlitelimab

fluticasone propionate

Levalbuterol

azelastine Hcl

Mometasone furoate

DUPIXENT®

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 23 total trials

A Study to Assess the Efficacy and Safety of Daily OM-85 in Young Children With Recurrent Wheezing

This study will assess the efficacy and safety of daily OM-85 treatment compared to placebo in children aged 6 months to 5 years with recurrent wheez...

Enrolling

Wheezing Lower Respiratory Illness

Recurrent Wheezing

Drug: OM-85

Drug: Placebo

A Trial to Learn if Dupilumab is Safe for and Helps Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis (ENGAGE)

The study is researching an experimental drug called dupilumab. The study is focused on participants with active eosinophilic gastritis (EoG) with or...

Enrolling

Eosinophilic Gastrointestinal Disease

Eosinophilic Gastritis

Drug: Dupilumab Dose 2

Drug: Matching Placebo

Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma (AIM4:Next Step)

This study is researching a drug called dupilumab. The study is focused on patients who have uncontrolled asthma. Asthma is a condition where the air...

Enrolling

Asthma

Drug: dupilumab

Drug: Matching Placebo

Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPD (AERIFY-3)

This study is an exploratory, two-part, 12-week, Phase 2a study to evaluate the mechanism of action of Itepekimab (anti-IL-33-mAb) and its impact on...

Active, not recruiting

Chronic Obstructive Pulmonary Disease

Drug: Itepekimab SAR440340